How consistently people take cholesterol-lowering injections
Part of Hormones & metabolism clinical trials.
This study looks at how consistently people take their cholesterol-lowering injections (inclisiran or evolocumab) in real life. It may help doctors understand what makes it easier or harder to stick with these medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been prescribed an injectable cholesterol medicine called inclisiran or evolocumab (Repatha) at least once.
- You must have a diagnosis of high cholesterol (dyslipidemia) or a related inherited condition.
- You must be at least 18 years old when you started the medicine.
- You must have had at least one doctor visit or prescription claim in the 7 months before starting.
- You should not have already been on these medicines before starting this treatment, unless it's your first time.
- This study is for people with complete insurance records for a full year after starting — if you switched insurers or passed away, you don't qualify.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who are starting one of three injectable cholesterol medications (inclisiran, evolocumab, or alirocumab) to see how well they stick with treatment over time. Understanding medication adherence helps doctors and patients find ways to improve long-term health outcomes.
This study looks at how well people stick with and respond to the cholesterol-lowering drug Inclisiran. It aims to understand if the medicine works well over time in Italian patients.
This study tests a new injectable medicine called inclisiran for people who are already on many medications and have high cholesterol. It is designed for those who cannot lower their cholesterol enough with statins, especially if they have diabetes or other heart risks.
This trial tests a new version of inclisiran, a cholesterol-lowering medicine, to see if it is safe and works well. The study compares it to the current version. You may qualify if you have moderately high cholesterol but have never taken cholesterol medications.
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
This study follows people who are already taking PCSK9 inhibitor shots to see how well patients stay on treatment and how effective it is. Your participation would mainly be about consenting to provide basic information and possibly follow-up details.
Hear when a new Dyslipidemia, Hypercholesterolemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.